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Introduction
The recent successes of genome-wide association studies and the
promises of whole genome sequencing fuel interest in the
translation of this new wave of basic genetic knowledge to health
care practice. Knowledge about genetic risk factors may be used to
target diagnostic, preventive, and therapeutic interventions for
complex disorders based on a person’s genetic risk, or to
complement existing risk models based on classical nongenetic
factors such as the Framingham risk score for cardiovascular
disease. Implementation of genetic risk prediction in health care
requires a series of studies that encompass all phases of
translational research [1,2], starting with a comprehensive
evaluation of genetic risk prediction.
With increasing numbers of discovered genetic markers that can
be used in future genetic risk prediction studies, it is crucial to
enhance the quality of the reporting of these studies, since valid
interpretation could be compromised by the lack of reporting of
key information. Information that is often missing includes details
in the description of how the study was designed and conducted
(e.g., how genetic variants were selected and coded, how risk
models or genetic risk scores were constructed, and how risk
categories were chosen), or how the results should be interpreted.
An appropriate assessment of the study’s strengths and weaknesses
is not possible without this information. There is ample evidence
that prediction research often suffers from poor design and bias,
and these may also have an impact on the results of the studies and
on models of disease outcomes based on these studies [3–5].
Although most prognostic studies published to date claim
significant results [6,7], very few translate to clinically useful
applications. Just as for observational epidemiological studies [8],
poor reporting complicates the use of the specific study for
research, clinical, or public health purposes and hampers the
synthesis of evidence across studies.
Reporting guidelines have been published for various research
designs [9], and these contain many items that are also relevant to
genetic risk prediction studies. In particular, the guidelines for
genetic association studies (STREGA) have relevant items on the
assessment of genetic variants, and the guidelines for observational
studies (STROBE) have relevant items about the reporting of
study design. The guidelines for diagnostic studies (STARD) and
those for tumor marker prognostic studies (REMARK) include
relevant items about test evaluation; the REMARK guidelines also
have relevant items about risk prediction [10–13]. However, none
of these guidelines are fully suited to genetic risk prediction studies,
an emerging field of investigation with specific methodological
issues that need to be addressed, such as the handling of large
numbers of genetic variants (from 10s to 10,000s) and flexibility in
handling such large numbers in analyses. We organized a two-day
workshop with an international group of risk prediction research-
ers, epidemiologists, geneticists, methodologists, statisticians, and
journal editors to develop recommendations for the reporting of
Genetic RIsk Prediction Studies (GRIPS).
Genetic Risk Prediction Studies
Genetic risk prediction studies typically develop or validate models
that predict the risk of disease, but they are also being investigated for
use in predicting prognostic outcome, treatment response, or
The Guidelines and Guidance section contains advice on conducting and
reporting medical research.
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treatment-related harms. Risk prediction models are statistical
algorithms, which may be simple genetic risk scores (e.g., risk allele
counts), may be based on regression analyses (e.g., weighted risk
scores or predicted risks), or may be based on more complex analytic
approaches such as support vector machine learning or classification
trees. The risk models may be based on genetic variants only, or
include both genetic and nongenetic risk factors [14].
Aims and Use of the GRIPS Statement
The 25 items of the GRIPS statement are intended to maximize
the transparency, quality, and completeness of reporting on
research methodology and findings in a particular study. It is
important to emphasize that these recommendations are guide-
lines only for how to report research and do not prescribe how to
perform genetic risk prediction studies. The guidelines do not
support or oppose the choice of any particular study design or
method, e.g., the guidelines recommend that the study population
should be described, but do not specify which population is
preferred in a particular study.
The intended audience for the reporting guidelines is broad and
includes epidemiologists, geneticists, statisticians, clinician scien-
tists, and laboratory-based investigators who undertake genetic risk
prediction studies, as well as journal editors and reviewers who
have to appraise the design, conduct and analysis of such studies.
In addition, it includes ‘‘users’’ of such studies who wish to
understand the basic premise, design, and limitations of genetic
prediction studies in order to interpret the results for their
potential application in health care. These guidelines are also
intended to ensure that essential data from future genetic risk
prediction studies are presented in standardized form, which will
facilitate information synthesis as part of systematic reviews and
meta-analyses.
Items presented in the checklist are relevant for a wide array of
risk prediction studies, because GRIPS focuses on the main aspects
of the design and analysis of risk prediction studies. GRIPS does
not address randomized trials that may be performed to test risk
models, nor does it specifically address decision analyses, cost-
effectiveness analyses, assessment of health care needs, or
assessment of barriers to health care implementation [15]. Once
the performance of a risk model has been established, these next
steps toward implementation require further evaluation [10,16].
For the reporting of these studies, which go beyond the assessment
of genetic risk models as such, additional requirements apply.
However, proper documentation of genetic predictive research
according to GRIPS might facilitate the translation of research
findings into clinical and public health practice.
Development of the GRIPS Statement
The GRIPS statement was developed by a multidisciplinary
panel of 25 risk prediction researchers, epidemiologists, geneticists,
methodologists, statisticians, and journal editors, seven of whom
were also part of the STREGA initiative [11]. They attended a
two-day meeting in Atlanta, Georgia (US) in December 2009 that
was sponsored by the US Centers for Disease Control and
Prevention on behalf of the Human Genome Epidemiology
Network (HuGENet) [17]. Participants discussed a draft version of
the guidelines that was prepared and distributed before the
meeting. This draft version was developed on the basis of existing
reporting guidelines, namely STREGA [11], REMARK [13], and
STARD [12]. These were selected out of all available guidelines
(see http://www.equator-network.org) because of their focus on
observational study designs and genetic factors (STREGA),
prediction models (REMARK), and test evaluation (REMARK
and STARD). During the meeting, methodological issues
pertinent to risk prediction studies were addressed in presenta-
tions. Workshop participants were asked to change, combine, or
delete proposed items and add additional items if necessary.
Participants had extensive post-meeting electronic correspon-
dence. To harmonize our recommendations for genetic risk
prediction studies with previous guidelines, we chose the same
wording for the items wherever possible. Finally, we tried to create
consistency with previous guidelines for the evaluation of risk
prediction studies of cardiovascular diseases and cancer [2,18].
The final version of the checklist is presented in Table 1.
The GRIPS Explanation and Elaboration Article
Accompanying this GRIPS statement, an Explanation and
Elaboration document has been written (see Text S1), modeled
after those developed for other reporting guidelines [19–22]. The
Explanation and Elaboration document illustrates each item with
at least one published example that we consider transparent in
reporting, explains the rationale for its inclusion in the checklist,
and presents details of the items that need to be addressed to
ensure transparent reporting. The Explanation and Elaboration
document was produced after the meeting. The document was
prepared by a small subgroup and shared with all workshop
participants for additional revisions and final approval.
Concluding Remarks and Future Directions
High-quality reporting reveals the strengths and weaknesses of
empirical studies, facilitates the interpretation of the scientific and
health care relevance of the results—especially within the
framework of systematic reviews and meta-analyses—and helps
build a solid evidence base for moving genomic discoveries into
applications in health care practice. The GRIPS guidelines were
developed to improve the transparency, quality and completeness
of the reporting of genetic risk prediction studies. As outlined in
the introduction, GRIPS does not prescribe how studies should be
designed, conducted, or analyzed, and therefore the guidelines
should not be used to assess the quality of empirical studies [23].
The guidelines should be used only to check whether all essential
items are adequately reported.
Summary Points
N The rapid and continuing progress in gene discovery for
complex diseases is fueling interest in the potential
application of genetic risk models for clinical and public
health practice.
N The number of studies assessing the predictive ability is
steadily increasing, but the quality and completeness of
reporting varies.
N A multidisciplinary workshop sponsored by the Human
Genome Epidemiology Network developed a checklist of
25 items recommended for strengthening the reporting
of Genetic RIsk Prediction Studies (GRIPS), building on
the principles established by prior reporting guidelines.
N These recommendations aim to enhance the transpar-
ency of study reporting, and thereby to improve the
synthesis and application of information from multiple
studies that might differ in design, conduct, or analysis.
N A detailed Explanation and Elaboration document is
published as supporting information (Text S1).
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Finally, the methodology for designing and assessing genetic risk
prediction models is still developing. For example, newer measures
of reclassification were first introduced in 2007 [24], and several
alternative reclassification measures have been proposed [25].
Which measures to apply and when to use measures of
reclassification are still subject to ongoing evaluation and
discussion [26]. Furthermore, alternative strategies for construct-
ing risk models other than simple regression analyses are being
explored, and these may add increased complexity to the
reporting. In formulating the items of the GRIPS statement, these
methodological advances were anticipated. It is for this reason that
the GRIPS statement recommends how a study should be
reported and not how a study should be conducted or analyzed.
Therefore, methodological and analytical developments will not
Table 1. Reporting recommendations for evaluations of risk prediction models that include genetic variants.
TITLE & ABSTRACT
1 (a) Identify the article as a study of risk prediction using genetic factors. (b) Use recommended keywords in the abstract:
genetic or genomic, risk, prediction.
INTRODUCTION
Background and rationale 2 Explain the scientific background and rationale for the prediction study.
Objectives 3 Specify the study objectives and state the specific model(s) that is/are investigated. State if the study concerns the
development of the model(s), a validation effort, or both.
METHODS
Study design and setting 4* Specify the key elements of the study design and describe the setting, locations, and relevant dates, including periods of
recruitment, follow-up, and data collection.
Participants 5* Describe eligibility criteria for participants, and sources and methods of selection of participants.
Variables: Definition 6* Clearly define all participant characteristics, risk factors and outcomes. Clearly define genetic variants using a widely-used
nomenclature system.
Variables: Assessment 7* (a) Describe sources of data and details of methods of assessment (measurement) for each variable. (b) Give a detailed
description of genotyping and other laboratory methods.
Variables: Coding 8 (a) Describe how genetic variants were handled in the analyses. (b) Explain how other quantitative variables were handled in
the analyses. If applicable, describe which groupings were chosen, and why.
Analysis: Risk model
construction
9 Specify the procedure and data used for the derivation of the risk model. Specify which candidate variables were initially
examined or considered for inclusion in models. Include details of any variable selection procedures and other model-
building issues. Specify the horizon of risk prediction (e.g., 5-year risk).
Analysis: Validation 10 Specify the procedure and data used for the validation of the risk model.
Analysis: Missing data 11 Specify how missing data were handled.
Analysis: Statistical methods 12 Specify all measures used for the evaluation of the risk model including, but not limited to, measures of model fit and
predictive ability.
Analysis: Other 13 Describe all subgroups, interactions, and exploratory analyses that were examined.
RESULTS
Participants 14* Report the numbers of individuals at each stage of the study. Give reasons for nonparticipation at each stage. Report the
number of participants not genotyped, and reasons why they were not genotyped.
Descriptives: Population 15* Report demographic and clinical characteristics of the study population, including risk factors used in the risk modeling.
Descriptives: Model estimates 16 Report unadjusted associations between the variables in the risk model(s) and the outcome. Report adjusted estimates and
their precision from the full risk model(s) for each variable.
Risk distributions 17* Report distributions of predicted risks and/or risk scores.
Assessment 18 Report measures of model fit and predictive ability, and any other performance measures, if pertinent.
Validation 19 Report any validation of the risk model(s).
Other analyses 20 Present results of any subgroup, interaction, or exploratory analyses, whenever pertinent.
DISCUSSION
Limitations 21 Discuss limitations and assumptions of the study, particularly those concerning study design, selection of participants, and
measurements and analyses, and discuss their impact on the results of the study.
Interpretation 22 Give an overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar
studies, and other relevant evidence.
Generalizability 23 Discuss the generalizability and, if pertinent, the health care relevance of the study results.
OTHER
Supplementary information 24 State whether databases for the analyzed data, risk models, and/or protocols are or will become publicly available and if so,
how they can be accessed.
Funding 25 Give the source of funding and the role of the funders for the present study. State whether there are any conflicts of interest.
* Marked items should be reported for every population in the study.
doi:10.1371/journal.pmed.1000420.t001
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immediately impact the validity and relevance of the items, but the
GRIPS statement will be updated when this is warranted by
essential new developments in the construction and evaluation of
genetic risk models.
Supporting Information
Text S1 Strengthening the Reporting of Genetic RIsk Prediction
Studies (GRIPS): Explanation and Elaboration.
Found at: doi:10.1371/journal.pmed.1000420.s001 (1.44 MB
DOC)
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